Orgenesis INC 8-K filings

Orgenesis has entered into an agreement to sell five mobile processing units and license its quality management system to Germfree for $8.34 million, while also establishing a long-term manufacturing and collaboration partnership.

Orgenesis Inc. has received an extension from Nasdaq until September 23, 2024, to meet the minimum $1.00 per share bid price requirement.

Orgenesis Inc. has successfully raised $2.3 million through a private placement to further its decentralized cell and gene therapy initiatives.

Orgenesis has entered into a binding term sheet with Germfree for the sale and leaseback of five OMPULs, along with a strategic collaboration framework, totaling $8.34 million and a $3.3 million working capital commitment.

Orgenesis Inc. has acquired all remaining equity interests of its subsidiary Octomera LLC from MM OS Holdings, L.P., solidifying its control over the company.

Orgenesis Inc. has entered into a binding term sheet to acquire all remaining equity interests of its subsidiary Octomera LLC from MM OS Holdings L.P.

Orgenesis Inc. amended its November 2023 Securities Purchase Agreement, agreeing to pay $277,500 to an investor to remove restrictions on future equity sales and terminate a related term sheet.